• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Astrazeneca enables patients to better manage COPD

Digital health program drives better medication and lifestyle management for COPD patients

Summary

  • Digital health program needed to support medication and lifestyle management
  • AstraZeneca and Clario collaborated on Me&My COPD, a mobile and digital technology solution
  • Patients enrolled into program by physicians
  • Program tailors care pathways to individual needs

Impact

  • Improved treatment adherence and identification of condition deterioration
  • Improved medication and lifestyle adherence
  • Decreased frequency of exacerbations and hospitalizations
  • Improved patient quality of life

Situation

AstraZeneca required a digital solution to support medication and lifestyle management for patients suffering from chronic obstructive pulmonary disease (COPD). The company needed a program with personalized self-management tools that respond to the individual’s needs in the right way, at the right time.

Solution

AstraZeneca collaborated with Clario to develop a digital health program called “Me&My COPD™”, which is implemented through Care Commissioning Groups (CCGs) in the UK healthcare system. Patient interaction is primarily via an app that captures daily diary and PEF readings via a Bluetooth® spirometer. Personalized goals and regular readings from a clinically-validated questionnaire are also tracked. The program is supported by a web portal which provides additional information relevant to each patient’s progress.

Patients can better manage their condition with tailored care pathways
and health tools, including:

  • Medical device tracking
  • Timely education and support
  • Management of clinic visits
  • Pulmonary rehabilitation offerings
  • Lifestyle management advice
Web portal on tablet

Web Portal provides additional information relevant to each patient’s progress

Personalized goals

Personalized goals tracked and coaching provided through digital program

Impact

Patients using Me&My COPD can collect, transmit and review their own clinical data in real-time. Additionally, they are able to benefit from improved medication and lifestyle management with care pathways, personalized coaching as well as goal management tools, individually tailored to their needs. The success of the program has led to a streamlined version now being rolled out globally in support of AstraZeneca’s brand.

Equip patients with the tools to take control of their health.